JANUARY 10, 2023
CARY, N.C., January 10, 2023 – Global biopharmaceutical services leader, Allucent, announced today the appointment of Alexander (Al) Berg, Pharm.D., Ph.D., FCP, as vice president of clinical pharmacology development and operations. In this important role, Dr. Berg will help guide strategy, drive business opportunities, and lead operations across Allucent’s Clinical Pharmacology, Model Informed Drug Development (MIDD), Pharmacometrics (PMx) and Pharmacokinetics/Pharmacodynamics (PK/PD) service offerings.
“With more than 14 years of experience in the pharmaceutical space, including roles as an operations executive, senior manager and consulting scientist, Al brings deep expertise and passion for converting complex data into knowledge that can guide critical decision-making and drive value for our small and mid-sized biotech partners,” said Katy Moore, president of clinical pharmacology modeling simulation at Allucent. “This appointment underscores Allucent’s commitment to bolstering our unsurpassed clinical pharmacology modeling simulation services during this time when we can harness data and technology to help our clients reduce costs, improve efficiencies, and increase the probability of success in developing medicines.”
Highlights of Dr. Berg’s career to date include:
- Serving as executive director of business development at Cognigen Corporation, a Simulations Plus Company – and then vice president of operations for the Cognigen Division of Simulations Plus – during which time he lead business and services operations and oversaw project management, technical writing, quality management and data management teams. As a senior consultant, Berg led multiple projects focused on clinical pharmacology in early clinical development and application of modeling and simulation to support global health initiatives.
- Serving as scientific director at the Critical Path Institute, where he led modeling and simulation efforts for the Critical Path to TB Drug Regimens Initiative, a collaboration with the Bill & Melinda Gates Foundation to advance novel therapies for the treatment of tuberculosis.
- Supporting drug development programs in neurology and oncology and leading internal and outsourced modeling and simulation activities for NDA, 505(b)(2), and ANDA filings as a clinical pharmacologist and clinical scientist within the pharmaceutical industry.
“The scientific innovation coming from small and mid-sized biotechs holds the potential to address some of today’s most pressing global health challenges,” said Dr. Berg. “I’m honored to join Allucent, where I can focus my expertise in applying clinical pharmacology and model-informed drug development strategies to guide smaller companies in designing efficient and effective clinical development programs in order to help bring needed medicines to patients around the world.”
Dr. Berg received his graduate training in Pharmaceutical Sciences (PhD) and Pharmacy Practice (PharmD) at North Dakota State University and was a post-doctoral fellow in clinical pharmacology at the Mayo Clinic. He is a recipient of the McKeen Cattell Award from the American College of Clinical Pharmacology (ACCP), an ACCP Fellow, and a registered pharmacist in the State of Minnesota. Dr. Berg has published numerous scientific papers in peer-reviewed journals and has presented on clinical pharmacology and pharmacometrics at national and international symposia.
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients. Visit Allucent.com for more information.